Galecto Inc
GLTO5.960USD
0.000
Market hours （ET）Quotes delayed by 15 min
7.89MMarket Cap
LossP/E TTM
More Details of Galecto Inc Company
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Galecto Inc Info
Ticker SymbolGLTO
Company nameGalecto Inc
IPO dateOct 29, 2020
CEODr. Hans T. Schambye, M.D., Ph.D.
Number of employees5
Security typeOrdinary Share
Fiscal year-endOct 29
Address75 State Street
CityBOSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02109
Phone14570705210
Websitehttps://galecto.com/
Ticker SymbolGLTO
IPO dateOct 29, 2020
CEODr. Hans T. Schambye, M.D., Ph.D.
Company Executives of Galecto Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Dr. Amy Wechsler, M.D.
Dr. Amy Wechsler, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Dr. Anne Prener, M.D., Ph.D.
Dr. Anne Prener, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David M. Shapiro, M.D.
Dr. David M. Shapiro, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Dr. Amy Wechsler, M.D.
Dr. Amy Wechsler, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Dr. Anne Prener, M.D., Ph.D.
Dr. Anne Prener, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Oct 11
Updated: Sat, Oct 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Goldfischer (Carl S)
3.17%
Danmarks Eksport- og Investeringsfond
2.23%
Renaissance Technologies LLC
1.10%
Susquehanna International Group, LLP
1.03%
Geode Capital Management, L.L.C.
0.70%
Other
91.78%
Shareholders
Shareholders
Proportion
Goldfischer (Carl S)
3.17%
Danmarks Eksport- og Investeringsfond
2.23%
Renaissance Technologies LLC
1.10%
Susquehanna International Group, LLP
1.03%
Geode Capital Management, L.L.C.
0.70%
Other
91.78%
Shareholder Types
Shareholders
Proportion
Individual Investor
3.68%
Venture Capital
2.23%
Investment Advisor
1.68%
Hedge Fund
1.17%
Investment Advisor/Hedge Fund
0.70%
Research Firm
0.10%
Other
90.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
44
164.38K
12.41%
-149.96K
2025Q2
59
237.90K
17.96%
-274.68K
2025Q1
62
239.03K
18.78%
-252.12K
2024Q4
60
217.43K
16.55%
-284.28K
2024Q3
59
203.99K
16.06%
-298.69K
2024Q2
60
348.76K
31.45%
-134.50K
2024Q1
63
345.52K
32.40%
-164.48K
2023Q4
60
341.29K
32.01%
-179.28K
2023Q3
64
397.38K
37.18%
-170.79K
2023Q2
66
515.37K
50.18%
-71.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Goldfischer (Carl S)
41.96K
3.17%
+1.00
+0.00%
Apr 15, 2025
Danmarks Eksport- og Investeringsfond
29.52K
2.23%
-29.52K
-50.00%
Sep 30, 2024
Renaissance Technologies LLC
14.54K
1.1%
-800.00
-5.21%
Jun 30, 2025
Susquehanna International Group, LLP
13.60K
1.03%
+2.88K
+26.86%
Jun 30, 2025
Geode Capital Management, L.L.C.
9.29K
0.7%
--
--
Aug 31, 2025
The Vanguard Group, Inc.
6.19K
0.47%
--
--
Aug 31, 2025
Schambye (Hans T.)
4.02K
0.3%
+625.00
+18.40%
Jul 03, 2025
UBS Financial Services, Inc.
2.31K
0.17%
+2.03K
+711.58%
Jun 30, 2025
Winslow (Garrett)
1.43K
0.11%
+420.00
+41.63%
Jul 03, 2025
BofA Global Research (US)
1.23K
0.09%
+2.00
+0.16%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Date
Type
Ratio
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
